What are the treatment options for involuntary movements, including acute drug‑induced dystonia and chronic conditions such as tardive dyskinesia, chorea, myoclonus, and focal dystonia?

Treatment of Involuntary Movements

For acute drug-induced dystonia, immediately administer anticholinergic or antihistaminic medications, which provide rapid and effective relief of this potentially life-threatening condition. 1

Acute Drug-Induced Dystonia

Acute dystonic reactions involve sudden spastic contractions of distinct muscle groups—commonly affecting the neck, eyes (oculogyric crisis), or torso. These reactions are distressing and can be life-threatening when laryngospasm occurs 1, 2.

Treatment Algorithm:

• First-line: Anticholinergic medications (e.g., benztropine, diphenhydramine) provide rapid symptom reversal 1, 3
• Alternative: Antihistaminic medications are equally effective 1
• Prevention: Consider prophylactic antiparkinsonian agents in high-risk patients (young age, male gender, high-potency antipsychotic use, history of dystonic reactions) 1

The evidence strongly supports anticholinergics as the definitive treatment, with the 2020 APA guideline providing a Level 1C recommendation for this approach 3.

Drug-Induced Parkinsonism

For antipsychotic-induced parkinsonism (bradykinesia, tremors, rigidity), use a stepwise approach 1:

1. Anticholinergic agents (first-line)
2. Mild dopaminergic agents (amantadine) as alternative
3. Dose reduction of the offending antipsychotic if clinically feasible
4. Switch to atypical antipsychotic 3

The 2020 APA guideline suggests these options with a 2C recommendation 3.

Akathisia

This severe restlessness is notoriously difficult to treat and frequently causes medication noncompliance 1:

Treatment Hierarchy:

1. Lower antipsychotic dose (if clinically feasible)
2. β-blockers (propranolol)—reported effective 1
3. Benzodiazepines—reported effective 1
4. Switch to different antipsychotic

Important caveat: Antiparkinsonian agents are NOT consistently helpful for akathisia, unlike dystonia or parkinsonism 1, 3.

Tardive Dyskinesia

For moderate to severe or disabling tardive dyskinesia, treat with a reversible VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor), which represents the only FDA-approved specific treatment. 3

Management Strategy:

Since there is no other specific treatment besides discontinuing the causative medication 1, follow this algorithm:

1. If patient is in full remission and dose change risks relapse: Continue current medication 1
2. Otherwise: Lower dose or switch to atypical antipsychotic (particularly clozapine) 1
3. For moderate-severe/disabling TD: Add VMAT2 inhibitor 3
4. Alternative options: Tetrabenazine, reserpine 4, 5

Critical monitoring requirement: Assess for dyskinesias every 3-6 months using the Abnormal Involuntary Movement Scale once neuroleptic therapy begins 1. Document baseline abnormal movements before starting treatment 1.

Important distinction: Withdrawal dyskinesias (occurring with medication cessation) almost always resolve over time, whereas tardive dyskinesia may persist permanently even after discontinuation 1.

Focal Dystonia (Non-Drug-Induced)

For focal dystonia including cervical dystonia and blepharospasm, botulinum neurotoxin injections are the primary treatment. 6

Specific Recommendations:

• Cervical dystonia: AboBoNT-A and rimaBoNT-B should be offered (similarly effective); onaBoNT-A and incoBoNT-A should be considered 6
• Blepharospasm: OnaBoNT-A and incoBoNT-A are equally effective and should be considered; aboBoNT-A is possibly effective 6

For persistent dystonia in children, the medication hierarchy includes 7:

1. Anticholinergics
2. Baclofen
3. Benzodiazepines
4. Botulinum toxin (particularly for focal forms)
5. Additional options: levodopa, gabapentin, clonidine, VMAT inhibitors

Chorea and Myoclonus

While the provided evidence focuses primarily on drug-induced movement disorders, treatment approaches for these conditions include 4, 8:

• Chorea: VMAT-2 inhibitors (tetrabenazine), dopamine receptor antagonists
• Myoclonus: Treatment depends on underlying etiology and specific subtype

Common Pitfalls to Avoid

1. Misdiagnosing akathisia as psychotic agitation or anxiety—this leads to inappropriate dose increases rather than the needed dose reduction or adjunctive treatment 1

2. Using antiparkinsonian agents for akathisia—they are not consistently helpful, unlike their effectiveness for dystonia and parkinsonism 1

3. Continuing prophylactic antiparkinsonian agents indefinitely—reevaluate need after acute phase, as many patients no longer require them during long-term therapy 1

4. Failing to obtain informed consent and baseline movement assessments before starting antipsychotics—this has both clinical and medicolegal implications 1

5. Confusing withdrawal dyskinesia with tardive dyskinesia—withdrawal dyskinesias resolve over time, while TD may be permanent 1